Nanologica Valuation

Is 4YD undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 4YD when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 4YD's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 4YD's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 4YD?

Key metric: As 4YD is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 4YD. This is calculated by dividing 4YD's market cap by their current revenue.
What is 4YD's PS Ratio?
PS Ratio	18.3x
Sales	SEK 8.76m
Market Cap	SEK 160.81m

4YD key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	18.3x
Enterprise Value/EBITDA	-2.6x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does 4YD's PS Ratio compare to its peers?

The above table shows the PS ratio for 4YD vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	3x
CNW co.don	0.7x	n/a	€6.5m
MDG1 Medigene	3x	16.1%	€22.6m
BPXA Bellicum Pharmaceuticals	0.5x	n/a	€772.4k
ECX Epigenomics	7.7x	n/a	€1.1m
4YD Nanologica	18.3x	95.5%	€160.8m

Price-To-Sales vs Peers: 4YD is expensive based on its Price-To-Sales Ratio (18.3x) compared to the peer average (3.8x).

Price to Sales Ratio vs Industry

How does 4YD's PS Ratio compare vs other companies in the DE Biotechs Industry?

6 Companies	Price / Sales	Estimated Growth	Market Cap
CNW co.don	0.7x	n/a	US$6.97m
V9Z Aceragen	0.4x	n/a	US$3.12m
PA8 Paion	0.2x	30.2%	US$2.78m
V9Z Aceragen	0.3x	-161.8%	US$2.18m

6 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: 4YD is expensive based on its Price-To-Sales Ratio (18.3x) compared to the European Biotechs industry average (7.9x).

Price to Sales Ratio vs Fair Ratio

What is 4YD's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

4YD PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	18.3x
Fair PS Ratio	20.2x

Price-To-Sales vs Fair Ratio: 4YD is good value based on its Price-To-Sales Ratio (18.3x) compared to the estimated Fair Price-To-Sales Ratio (20.2x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Aspen Pharmacare Holdings

R75.5b

Manufactures and supplies specialty and branded pharmaceutical products worldwide.

LDZA

R8.95

0.6%

4.7%

Amneal Pharmaceuticals

US$2.6b

Develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide.

2DT

US$7.70

-4.3%

91.5%

Collegium Pharmaceutical

US$966.2m

A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

354

US$29.00

5.1%

22.9%